More ques­tions than an­swers for bio­phar­ma af­ter UK elec­tion; In­ter­cept gets FDA ad­vi­so­ry date, and a PDU­FA de­lay

→ On Thurs­day, vot­ers in the UK hand­ed Boris John­son’s Con­ser­v­a­tive gov­ern­ment, and its ag­gres­sive Brex­it stance, a clear ma­jor­i­ty. Urte Jaki­mavi­ciute, Glob­al­Da­ta‘s se­nior di­rec­tor of mar­ket re­search, weighed in on the biotech im­pli­ca­tions.

“The phar­ma sec­tor has been al­lo­cat­ing sig­nif­i­cant amounts of mon­ey to deal with any po­ten­tial con­se­quences of Brex­it, and with Con­ser­v­a­tives win­ning the elec­tion, Boris John­son’s with­draw­al agree­ment should be backed by the UK’s par­lia­ment. Even though the UK is set to leave by Jan­u­ary 31, it is un­clear what kind of re­la­tion­ship with the EU Boris John­son will seek. No mat­ter what con­tin­gency plans are in place and how much funds phar­ma com­pa­nies are al­lo­cat­ing to deal with the con­se­quences of Brex­it, it is very hard to be ready for what­ev­er is go­ing to hap­pen due to an enor­mous de­gree of un­cer­tain­ty sur­round­ing the process. You can­not ful­ly pre­pare for some­thing that you can­not con­trol.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER